Abstract
37 patients with cutaneous malignant melanoma (MM) were randomized, after surgical removal of tumor, to either no further treatment or to adjuvant treatment by the thymic factor thymostimulation (TS; Tp-1 Serono®). 26 patients were with primary (stage I) MM (tumor thickness > 1.25 mm), and 11 patients with local or regional disease spread (stage II MM). Randomization was done separately for each disease stage. Life table analysis of the results indicates that significantly (p < 0.01) more patients were free of disease after one year of study if treated by TS than if left untreated. Probability of survival was also better (p = 0.05) in the TS-treated group at 15 months of study. No side effects, toxic or allergic, were observed under TS treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 1043-1046 |
| Number of pages | 4 |
| Journal | Arzneimittel-Forschung/Drug Research |
| Volume | 34 |
| Issue number | 9 |
| State | Published - 1984 |
| Externally published | Yes |